^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sirolimus

i
Other names: AY 22989, NSC 226080, NPC-12
Company:
Generic mfg.
Drug class:
mTOR inhibitor
1d
Schisandrin C suppresses melanoma growth and metastasis through modulation of Rap1-related and phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathways. (PubMed, Melanoma Res)
In vivo, Sch C markedly reduced tumor volume and weight without obvious toxicity and increased apoptosis while decreasing proliferation in tumor tissues. Sch C exerts antimelanoma effects and is associated with inhibition of PI3K/AKT/mTOR signaling and modulation of Rap1-related pathways, suggesting its potential as a therapeutic candidate for melanoma.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
sirolimus
2d
Activation of PPARγ/FGF21 signaling axis with Puerarin reprograms tumor lipid metabolism, attenuating malignancy in colon cancer. (PubMed, Phytomedicine)
Puerarin halted the malignant progression of CRC by reprogramming tumor lipid metabolism. Puerarin thus hold promise as a clinically deployable lipid-centric agent that could synergistically potentiate conventional anticancer drugs.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • FGF21 (Fibroblast Growth Factor 21) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PI3K (Phosphoinositide 3-kinases)
|
sirolimus
2d
Inhibiting fear memory recall-induced oligodendrogenesis rescues PTSD-like behaviors. (PubMed, Mol Psychiatry)
More importantly, administering rapamycin, a potent inhibitor of oligodendrogenesis, during repeated fear recalls phenocopies the effects of anti-myelination on fear memory-related behavioral defects...Pharmacological treatments that inhibiting oligodendrogenesis during the recall phase represent a promising therapeutic strategy for preventing the pathological reinforcement of long-term fear memories, thereby averting the emergence of anxiety-like behaviors and social preference deficits in individuals with PTSD. Schematic image summarizing the major findings of the present study.
Journal
|
OLIG2 (Oligodendrocyte Transcription Factor 2)
|
sirolimus
3d
MOG-Peptide Synergizes With Rapamycin to Drive CD4+ T Cells Into Protective Antigen-Specific Tregs in EAE. (PubMed, Immunology)
The underlying mechanism of this phenomenon was associated with the modulation of autophagic pathways by rapamycin, encouraging the differentiation of naïve CD4 T cells into MOG35-55-specific Tregs, as evidenced by tetramer staining. These findings provide a conceptual framework for exploring strategies aimed at promoting antigen-specific tolerance in autoimmune diseases.
Journal
|
CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
|
sirolimus
5d
In vitro study of TSC1 deficiency in preadipocytes: insights into development and treatment options for tuberous sclerosis related lipomatosis. (PubMed, Orphanet J Rare Dis)
This study highlights the need for further investigation into the efficacy of pathway inhibitors in managing TSC-related lipomas in vivo and offers a potential treatment avenue for patients suffering from recurrent lipomatosis.
Preclinical • Journal
|
TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
Piqray (alpelisib) • sirolimus
6d
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder (clinicaltrials.gov)
P2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2026 --> Jun 2028
Enrollment closed • Trial primary completion date • Tumor mutational burden
|
RUNX1 (RUNX Family Transcription Factor 1)
|
sirolimus
6d
Redox Imbalance in Gestational Diabetes Mellitus: Mechanistic Insights, Emerging Biomarkers, and Therapeutic Perspectives. (PubMed, Int J Mol Sci)
These converging mechanisms culminate in profound placental maladaptation, including structural abnormalities like chorangiosis and functional defects in nutrient transport mediated by hyperactive mechanistic target of rapamycin complex 1 (mTORC1) signaling. This review article provides insight into recent evidence to elucidate the meta-inflammatory environment of GDM, where modest but sustained elevations in biomarkers like Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) disrupt redox homeostasis and impair insulin signaling pathways through the activation of stress-sensitive kinases. By integrating these molecular perspectives, the article underscores the necessity of targeting the systemic inflammatory and oxidative continuum spanning pre-conception to the antenatal period through lifestyle interventions and emerging therapeutic strategies to mitigate GDM risk and improve maternal-fetal outcomes.
Review • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MAPK8 (Mitogen-activated protein kinase 8)
|
sirolimus
6d
H3K18la- driven neutrophil secretory autophagy promotes pulmonary endothelial dysfunction in sepsis-induced lung injury. (PubMed, Autophagy)
Our findings uncover a metabolically driven, epigenetically regulated secretory autophagy pathway in neutrophils that mediates endothelial dysfunction. Our study provides mechanistic insights into neutrophil-endothelial crosstalk in sepsis and identifies EP300, ATG7, and IL1B as potential therapeutic targets for sepsis.Abbreviations: ALI: acute lung injury; ANOVA: analysis of variance; ATF4/CREB-2: activating transcription factor 4; ATG7/GSA7: autophagy related 7; ATP: adenosine triphosphate; BafA1: bafilomycin A1; BMDN: bone marrow-derived neutrophil; C-CASP1: cleaved-caspase 1; CDH5/CD144: cadherin 5; CRP/PTX1: C-reactive protein; CST3: cystatin C; CXCL8/IL-8: C-X-C motif chemokine ligand 8; DAPI: 4',6-diamidino-2-phenylindole; DEG: differentially expressed gene; dHL-60: dimethyl sulfoxide-differentiated HL-60 cell; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent assay; EP300/p300: EP300 lysine acetyltransferase; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic - pyruvic transaminase; GSDMD-N: gasdermin D N-terminal; H&E: hematoxylin and eosin; H3K18la: histone H3K18 lactylation; HRP: horseradish peroxidase; ICU: intensive care unit; IHC: immunohistochemistry; IL1B/IL-1B: interleukin 1 beta; IL1R1/CD121A: interleukin 1 receptor type 1; IL6/IL-6: interleukin 6; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAMP1/CD107a: lysosome associated membrane protein 1; LDHA: lactate dehydrogenase A; LPS: lipopolysaccharide; 3-MA: 3-methyladenine; NLRP3/NALP3: NLR family pyrin domain containing 3; PBS: phosphate-buffered saline; PCT: procalcitonin; PMN: peripheral neutrophils; Rapa: rapamycin; RNA-seq: RNA-sequencing; SERPINE1/PAI1: serpin family E member 1; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; SOFA: Sequential Organ Failure Assessment; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TNF/TNF-alpha: tumor necrosis factor; panKla: pan-histone lactylation; VCAM1/CD106: vascular cell adhesion molecule 1.
Journal
|
LDHA (Lactate dehydrogenase A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • EP300 (E1A binding protein p300) • SQSTM1 (Sequestosome 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • SERPINE1 (Serpin Family E Member 1) • ATF4 (Activating Transcription Factor 4) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • NLRP3 (NLR Family Pyrin Domain Containing 3) • PRDX2 (Peroxiredoxin 2) • VCAM1 (Vascular Cell Adhesion Molecule 1) • ATG7 (Autophagy Related 7) • CDH5 (Cadherin 5) • CRP (C-reactive protein) • TCF4 (Transcription Factor 4)
|
sirolimus
6d
Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study. (PubMed, Pol Arch Intern Med)
 In routine practice, sirolimus was associated with long-term stabilization of lung function, marked improvement of lymphatic disease, reduction of angiomyolipoma burden, and acceptable tolerability. VEGF-D aligned with lymphatic phenotype and declined with treatment, supporting its role as a monitoring biomarker.
Retrospective data • Journal
|
VEGFD (Vascular Endothelial Growth Factor D)
|
sirolimus
6d
Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia. (PubMed, Biomed Pharmacother)
The selective HDAC6 inhibitor 7b induced sustained α-tubulin acetylation at lower concentrations than ricolinostat or nexturastat A. 7b reduced primary CML PBMC viability while sparing healthy PBMCs and was active in vivo...ISR activation occurred downstream of the autophagy disruption: rapamycin attenuated ISR activation, whereas ATG7 silencing intensified ISR signaling and apoptosis...The combination elicited immunogenic cell death markers: calreticulin exposure, ATP and HMGB1 release, elevated TNF-α, and reduced IL-8. These findings identify HDAC6-driven autophagy as a therapeutically exploitable vulnerability in CML that, when combined with asciminib, triggers ISR-dependent immunogenic apoptosis.
Journal
|
BCR (BCR Activator Of RhoGEF And GTPase) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CASP9 (Caspase 9) • ATF4 (Activating Transcription Factor 4) • ATG7 (Autophagy Related 7) • CASP10 (Caspase 10)
|
BCR-ABL1 fusion
|
sirolimus • Scemblix (asciminib) • rocilinostat (ACY-1215) • nexturastat A
7d
Network pharmacology of Sijunzi decoction in pancreatic cancer. (PubMed, Chin Clin Oncol)
This study clarifies the active components, targets, and mechanisms of SJZD in treating PDAC, offering insights into the therapeutic potential of TCM.
Journal
|
ER (Estrogen receptor) • TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
|
sirolimus